The transition from reference to biosimilar etanercept was safe and effective in patients with stable rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA), according to updated findings from the BENEFIT study.
The transition from reference to biosimilar etanercept was safe and effective in patients with stable rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA), according to updated findings from the BENEFIT study, based on observed declines in disease activity.
Investigators evaluated clinical records of adult patients in France, Germany, Italy, and Spain. The real-world study employed Samsung Bioepis’ etanercept biosimilar, SB4, which is approved in multiple markets and distributed under the names Benepali, Brenzys, and Eticovo. It received FDA approval in 2019 but is not expected to come to market until 2029.
The investigators enrolled 358 patients with RA and 199 patients with axSpA. They used the Disease Activity Score 28 (DAS28) to measure changes in RA and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for axSpA.
DAS28 assigns a score from 1 to 10 based on tenderness and swelling in 28 bodily joints, with higher scores being more disease severity. In the study, the mean individual DAS28 change following transition from reference (Enbrel) was —0.02 (95% CI, –0.11 to 0.08) at 3 months and 0.01 (95% CI, –0.09 to 0.11) at 6 months.
BASDAI assigns a score of 1 to 10 based on fatigue, spinal pain, joint pain and swelling, tenderness, and stiffness. Among patients with axSpA, the 3- and 6-month values for BASDAI were —0.01 (95% CI, –0.24 to 0.21) and –0.11 (95% CI, –0.31 to 0.10), respectively.
Among patients with RA, 19 (5.3%) experienced adverse events and 5 (1.4%), serious adverse events (SAEs). The respective numbers for patients in the axSpA cohort were 12 (6%) and 2 (1%). Investigators said an SAE of pneumonia in the RA cohort was considered SB4 related.
At 6 months, 90.8% of patients remained on SB4, compared with 92.4% in the axSpA group.
The updated findings correlate with data reported from BENEFIT last year at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology.
Reference
Selmi C, Krüger K, Cantagrel A, et al. BENEFIT: real-world effectiveness of SB4 after transition from reference etanercept in rheumatoid arthritis and axial spondyloarthritis. Clin Exp Rheumatol. Published online Jun 30, 2020. https://pubmed.ncbi.nlm.nih.gov/32662409/
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Meta-Analysis Confirms Similar Safety, Efficacy Between Adalimumab Biosimilars, Humira
April 6th 2024A systematic review and meta-analysis of 7 randomized controlled trials found no significant differences in efficacy and safety indicators between adalimumab biosimilars and the reference product (Humira) for treatment of moderate to severe psoriasis.